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Abstract 
 
Background 
Prognostic biomarkers aim to improve on the current inadequate method of 
identifying patients with oral epithelial dysplasia at greatest risk of malignant 
transformation, namely histological assessment. We aimed to assess the prognostic 
ability of 6 protein biomarkers linked to the EGFR and associated tetraspanin 
pathway, along with clinical parameters, in a large multicentre oral dysplasia cohort. 
Methods 
148 cases with varying degrees of epithelial dysplasia underwent 
immunohistochemistry. The markers assessed were CD9, CD151 and CD82, EGFR, 
Her-2, and Cyclooxygenase-2 (COX-2). Scoring was performed independently by 
two observers. Univariate analyses using both logistic and Cox regression models 
and a multivariate regression were performed. 
Results 
Malignant progression was significantly greater in those cases with decreased 
expression of CD9 (p=0.02), and increased expression of CD151 (p=0.02), EGFR 
(p=0.04) and COX-2 (p=0.003). Histological grade (p=0.0002), and morphology 
(p=0.03) were also prognostic, whilst smoking and alcohol were not. The optimal 
combination by backward variable selection was histological grade (hazard ratio 
1.64; 95% CI 1.12, 2.40), COX-2 over-expression (HR 1.12; 1.02, 1.24) and CD9 
under-expression (HR 0.88; 0.80, 0.97). CD82 and Her-2 demonstrated no 
prognostic ability. 
Conclusions 
This is the first study of the expression and prognostic potential of the tetraspanins in 
oral dysplasia. A combination of certain biomarkers with clinical factors appeared to 
improve the accuracy of determining the risk of malignancy in individuals with oral 
dysplasia. These findings may also offer potential new therapeutic approaches for 
this condition.  
 
Introduction 
Cancers of the oral cavity arise through a combination of progressive genomic 
alteration and exposure to environmental carcinogens2. Many OSCCs arise in areas 
of genomic and histological abnormality, termed oral epithelial dysplasia (OED). The 
degree of cytological and architectural abnormality seen on histological examination 
is used to assign a grade of severity to OED3,4. Quantifying the risk of transformation 
of an individual OED lesion to cancer is complex, due to both a lack of knowledge of 
the natural history of OED and because of the wide variability in reported 
transformation rates in the published literature (5% to 36%)5,6. A recent meta-
analysis estimated the malignant transformation of OED to be 12% (95% CI 8-18%)7. 
Furthermore, while dysplasia grade assessed by histological examination is currently 
the best predictor of future malignant behaviour, it has significant limitations. Despite 
more severe grades of dysplasia being associated with higher transformation rates, 
cases with mild dysplasia may still progress to cancer, while a significant proportion 
with severe dysplasia do not transform, irrespective of environmental factors1,3,4,7,8. In 
addition, histological grading of OED is known to be largely subjective, resulting in 
significant inter and intra-rater variability9-12. This results in histological grading 
having only a moderate prognostic ability at best. However, it remains the gold 
standard on which treatment decisions are based13.  
The differential expression of biomarkers in cancer, potentially malignant lesions and 
normal mucosa offers the possibility of better identification of those lesions with the 
highest risk of malignant progression. To date, many biomarkers have been 
described, yet due to low sample size and methodological limitations, few have been 
validated and none have as yet been incorporated into routine clinical use. The 
search for effective prognostic biomarkers for this indication continues.  
The Epidermal Growth Factor receptor (EGFR) family has been extensively studied 
in relation to cancer biology. Strong evidence exists for their role in carcinogenesis in 
many solid tumours, including those arising in the breast, ovary, colon and lung14. 
Overexpression of EGFR occurs in around 80% - 90% of head and neck cancers and 
in some studies has been shown to be correlated with worse survival outcomes15-17. 
Another of the EGF family, Her2 is also upregulated in oral dysplasia and cancer5,6,18. 
This pathway is also of interest in as there are already several molecular therapies 
targeted against EGFR; including small molecule tyrosine kinase inhibitors (e.g. 
gefitinib) and monoclonal antibodies (e.g. cetuximab), which may potentially be of 
benefit for the treatment of OED.  
Our aim was to examine the prognostic potential of EGFR and associated 
biomarkers known to regulate this pathway, along with clinical factors in one of the 
largest cohorts of OED reported in the literature. 
  
Methods 
This study has been reported using the REporting recommendations for tumour 
MARKer prognostic studies (REMARK) guidelines19. Ethical approval was granted 
from the Coventry research ethics committee (06/Q2802/79) and the Human 
Biomaterials Resource Centre at the University of Birmingham (10-008).  
 
Patient selection  
This was a retrospective cohort study. Consecutive cases were selected after 
systematic searching of the pathology archives from 5 institutions: University Hospital 
Coventry and Warwickshire, University Hospital Birmingham, Birmingham Dental 
Hospital, George Eliot Hospital Nuneaton, and the University Of Leeds. Searching 
was performed using the Systematized Nomenclature of Medicine Clinical Terms 
(SNOMED) and free field text, to include any biopsies taken between 1996 and 2008. 
Inclusion in the cohort required patients to be over 18 years of age at time of biopsy 
(no upper age limit was set), have a confirmed diagnosis of OED using the WHO 
classification system, and have a minimum follow-up for non-transformed cases of 12 
months, or transformation to cancer after 3 months of diagnosis of OED. Where 
several biopsies were available from a single patient, the first diagnostic biopsy was 
used. Where the first diagnostic biopsy was not available, the next oldest biopsy was 
used. Cases were excluded if positive for candida on diastase-resistant periodic acid 
schiff (dPAS) staining, along with diagnoses of lichenoid inflammation with atypia 
(histological changes are likely a result of inflammation and therefore represents a 
different process to true neoplastic change) and proliferative verrucous leukoplakia. 
Any patient with OED that had a previous diagnosis of head and neck cancer 
(identified either through the pathology database or a search of the clinical records) 
was excluded, as this population of patients are known to already be at increased 
risk of developing a second malignancy, and previous treatment may have affected 
the behaviour of the lesion under investigation. Clinical information on the exposure 
to known or suspected risk factors such as age, sex, anatomical site, lesion 
morphology and smoking/alcohol history were collected.  
 
Immunohistochemistry 
All samples were taken from formalin-fixed, paraffin-embedded tissue. 4μm sections 
were taken either from donor blocks or a tissue microarray containing some of the 
cases. We have previously demonstrated near perfect agreement in 
immunohistochemical scoring between tissue microarrays and slides using these 
biomarkers in OED7,20. After deparaffinsation in xylene, sections were rehydrated in 
distilled water. Unmasking of the epitopes was performed using a PickCell antigen 
retrieval unit, exposing the samples to both heat and pressure while in Tris-
ethylenediaminetetraacetic acid (EDTA) buffer concentrate at pH7.8, or Citrate buffer 
pH6 (determined by prior optimisation and validation). The Novocastra™ Polymer 
Detection System was used for this study. Endogenous peroxidase and protein was 
blocked with 3% hydrogen peroxide and 0.4% Casein in phosphate-buffered saline 
respectively. Slides were then incubated at 4°C with monoclonal antibodies at 
optimal concentrations (supplementary table 1). After 30 minute incubations with post 
primary block and polymer, 3,3'-Diaminobenzidine (DAB) working solution was 
applied for five minutes. Application of Mayer’s haematoxylin for 1 minute provided 
counterstaining. All positive controls stained correctly and no negative controls 
demonstrated any staining during the procedure.  
 
 
Immunohistochemical scoring 
Two individual raters, with different levels of experience in immunohistochemistry 
assessment, independently scored each case. Raters were blinded to the clinical 
details of the case. It has been suggested that when scoring immunoreactivity in 
small specimens (such as OED specimens examined here) only the area with 
maximal staining should be interpreted21. This approach was applied here. The 
sections were presented in random order to the raters with cases of disagreement 
undergoing consensus scoring. Antibody expression was determined by assessing 
the intensity and proportion of cells stained. Staining intensity was scored from 0 to 
3: 0 = negative (No staining); 1 = weak staining; 2 = moderately strong staining; and 
3 = strong staining. Proportion was also scored on a 4-point scale: 1 (<25% of cells 
stained); 2 (25-50% of cells stained); 3 (51-75% of cells stained); 4 (>75% cells 
stained). An overall score for each case was generated by the sum of the intensity 
and proportion scores, resulting in a range of scores from 0 to 12.  
 
Statistical analysis 
Scoring agreement between raters was calculated using a kappa statistic (κ) and 
intraclass correlation coefficients (ICCC). The latter measure is felt to be superior 
when correlating immunohistochemistry scores between raters, as it is calculated 
using the whole range of data, thereby not being influenced on how the data is 
categorised, as is the case with kappas22. However, many studies quote kappa 
scores and hence they were also included here to allow comparison.  Kappa scores 
were interpreted using a scale proposed by Landis and Koch, with scores of 0 – 0.2 
representing slight, 0.2 – 0.4 fair, 0.4 – 06 moderate, 0.6 – 0.8 substantial and 0.8 – 
1.0 near perfect agreement23. An ICCC of < 0.40 was regarded as poor, 0.4-0.59 as 
fair, 0.6 – 0.74 as good, >0.74 as excellent and 1 perfect correlation24. Consensus 
scores between the two raters were used for subsequent analyses. The capability of 
each biomarker or clinical factor to predict progression was initially calculated using 
univariate logistic regression. Consideration of the additional effect of time on the 
prognostic ability was assessed using a Cox regression analysis, with significance 
defined as p<0.05. Clinical factors were analysed as categorical variables as shown 
in table 1. Missing data was handled using listwise deletion, where any cases with 
missing clinical data were excluded from the analysis of that particular variable. 
Multivariate analysis with backwards variable selection was performed to examine 
which factors remained independent indicators of transformation. This method 
negates one of the disadvantages of forward variable selection, whereby addition of 
each new variable to the model may make a previously significant variable, non-
significant.  
To further explore the scoring thresholds that predict progression, a logistic 
regression was performed on the continuous immunohistochemistry scores. Where a 
linear effect was not seen, scores were then converted to categorical variables to 
examine whether prognostic ability differed between these categories. Categorisation 
was as follows: score of 0 = 0 (truly negative), scores of 1-4 = 1 (weakly positive), 5-8 
= 2 (moderately positive), >9 = 3 (strongly positive). Finally, Pearson chi-squared 
analysis was used to identify the optimal binary scoring threshold to group cases into 
the most and least likely to transform. Oral cancer free survival was calculated for 
these different groups using Kaplan Meier survival curves. Differences between the 
resulting curves were calculated using a Log-rank (Mantel-Cox) test. Calculations 
were performed using SPSS version 19.0 for Mac; SPSS Inc., Chicago, IL, USA and 
SAS version 9.2.  
Results 
Characteristics of patients in this cohort  
The 148 patients included in this cohort of patients with OED were almost equally 
male (76) and female (72). The mean age was 61 years (SD 13.6) with a range from 
19 to 90. Other demographic data including OED dysplasia grade is summarised in 
table 1. 39 cases out of 148 progressed from dysplasia to cancer (26%) with a 
median time to transformation for these cases of 26 months.  
 
Inter-rater scoring reliability  
There was strong agreement between the two raters for all biomarkers used in this 
study. Kappa scores ranged from 0.66 to 1.0, demonstrating substantial agreement. 
This finding was confirmed with intraclass correlation coefficients ranging from 0.82 – 
1.0 (supplementary table 2). The most significant disagreement was seen on scoring 
the intensity of COX2 staining (k 0.66; ICCC 0.85) and proportion of EGFR cells 
stained (k 0.74; ICCC 0.82). This still represents substantial agreement.  
  
Prognostic ability of clinical factors 
Using a univariate logistic regression, higher grades of dysplasia were seen to 
significantly predict malignant transformation in this cohort (p=0.0002). This remained 
significant when time to transformation was analysed using a Cox regression model 
(p=0.001). The morphology of the individual lesions was also associated with 
progression (p=0.03). In ascending order, the proportion of progressors for each 
morphological type was: leukoplakia (17/94, 18%), ulcerated lesions (7/22, 32%), 
speckled lesions (5/13, 38%), mass lesions (2/4, 50%) and erythroplakia (8/15, 53%). 
However, morphology did not remain independently significant once added to grade 
in a multivariate analysis. Anatomical site, smoking and alcohol consumption were 
not prognostic (p=0.73, 0.29 and 0.61 respectively). Gender did not independently 
predict progression, yet showed a trend towards significance when added with 
histological grade into the multivariate model, with females more at risk than males 
(p=0.05).   
 
Prognostic ability of biomarkers 
Immunohistochemical expression of each of the biomarkers is summarised in 
supplementary table 3. The pattern of staining was predictable, with CD9, CD151, 
CD82 and EGFR localising to the cell membrane, and COX2 to the cytoplasm 
(figures 1 and 2). Only 8 out of the 148 cases demonstrated any Her2 staining, with 
all of these being membranous in location. Nearly 80% of cases had very weak or no 
CD82 staining (scores ≤3). Both raters agreed that scoring was not possible in 4 out 
of 888 slides (0.5%) because of inadequate tissue.  
Univariate logistic regression demonstrated a significantly increased risk of 
progression to cancer in cases with under-expression of CD9 (p=0.02) or over-
expression of CD151 (p=0.02), EGFR (p=0.04) or COX2 (p=0.003). When also 
considering time to transformation, CD9 (p=0.02), EGFR (p=0.04) and COX2 
(p=0.008) were still able to significantly predict progression (table 2). On multivariate 
analysis, CD9 (p=0.009) and COX2 (p=0.008) remained significant independent 
predictors of transformation to oral cancer. EGFR was not independently significantly 
associated with transformation on multivariate analysis. 
Logistic regression was performed in an attempt to more accurately define relevant 
scoring thresholds for the biomarkers with prognostic potential. COX2 was the only 
marker to demonstrate a clear linear effect, with increasing scores associated with 
increasing risk of malignant progression (p=0.002). No linear effect was seen with the 
other markers, even after the continuous scores (0-12) were converted to categorical 
variables. Pearson chi-squared analysis identified the optimal scoring thresholds to 
divide cases into those most and least likely to undergo malignant transformation. 
For CD9 and CD151, the threshold was between those cases scoring 0 or 1 versus 
the rest (2-12) (p<0.0001and 0.0002 respectively), and 0-2 versus the rest (3-12) for 
EGFR (p=0.006) (figure 3).  
Because CD9 has been postulated to have an action via direct effects on EGFR 
expression, any association between these markers was explored.  Yet, the 
correlation was low (0.04), with no evidence of an association between them in cases 
undergoing progression or not.  
 
Prognostic ability of clinical factors and biomarkers 
In combining both the clinical factors and biomarkers, the overall best combination by 
backwards variable selection was high dysplasia grade (hazard ratio 1.64; 95% CI 
1.12, 2.40, p=0.01), COX2 over expression (HR 1.12; 95% CI 1.02, 1.24, p=0.02) 
and under expression of CD9 (HR 0.88, 95% CI 0.80, 0.97, p=0.01) (table 3).  
  
Discussion 
This is the first study to examine the expression of members of the tetraspanin family 
in OED and the first to demonstrate a prognostic ability of CD9, CD151, COX2 and 
EGFR in a retrospective longitudinal oral epithelial dysplasia cohort. Decreased 
expression of CD9 was associated with a significantly increased risk of malignancy, 
especially when expression was almost completely absent (scores of 0 or 1; 
p<0.0001). Increased expression of CD151, EGFR and COX2 were similarly 
associated with malignant transformation. Immunohistochemical scores of greater 
than 2 and 3 for CD151 and EGFR respectively were significant (p=0.0002 and 0.006 
respectively). COX2 demonstrated a much more linear effect, as increasing 
expression correlated with increasing risk of cancer. Her2 and CD82 had no 
prognostic ability in this cohort and indeed demonstrated little expression overall in 
dysplastic tissues. CD9 and COX2 remained independently prognostic when 
accounting for the effect of other variables on multivariate analysis (p=0.009 and 
0.007 respectively). When both clinical factors and biomarkers were included in 
multivariate analysis, the best combination for predicting malignant progression was 
high dysplasia grade (hazard ratio 1.64) strong COX2 staining (HR 1.12) and weak 
CD9 staining (p=0.01). 
As might have been expected, increasing severity of dysplasia and erythroplakic 
lesions had higher malignant transformation rates on univariate logistic regression 
(p=0.0002 and 0.03 respectively). The anatomical site within the oral cavity was not 
prognostic in this cohort, which may in part be explained by the slightly low numbers 
of known high-risk floor of mouth lesions (13%), along with the grouping of all tongue 
lesions together (ventral tongue lesions are known to higher rates of transformation 
than others). Alcohol and smoking consumption were similarly not prognostic in this 
cohort. This is in keeping with other studies, where these habits have been 
demonstrated to increase the likelihood of developing potentially malignant lesions 
but not their subsequent malignant transformation{Napier:2008gz, Liu:2010ea}. 
Gender was also not independently prognostic, however females were more at risk 
when included in a multivariate analysis in combination with histological grade.  
The tetraspanins are a family of 33 proteins that form web complexes on the cell 
surface. When joined by gangliosides and cholesterol these aggregations are termed 
tetraspanin enriched microdomains25. Through these domains the tetraspanins are 
able to organise other transmembrane molecules including growth factor receptors9-
12,26, integrins13,27, and G-protein coupled receptors14,25,28. Because of the strong 
association with integrins and growth factor receptors, tumorigenic processes such 
as cell adhesion, motility, invasion and angiogenesis may be modulated and 
controlled. There have been relatively few studies examining the role tetraspanins 
play with specific regards to head and neck cancer, and none examining them in 
OED. However, the findings of these studies support our results. Decreased 
immunohistochemical expression of CD9 was detected in 42% of 129 oral cancer 
samples, with these cases significantly associated with regional nodal metastases 
(p=0.017) and a reduced overall and disease-free 5-year survival (p=0.071, p=0.01 
respectively)15-17,29. In the same study, 80% of cases had reduced or absent CD82 
staining, however no correlation with disease-free or overall survival was observed29. 
A study of 34 patients with head and neck cancer identified the same prolongation of 
overall and disease free survival (p=0.02; 0.004) with lower recurrence rates and 
stage of regional lymphadenopathy (p=0.02; 0.04) in cases with increased CD9 
expression30. Decreased CD9 expression was also seen in lymphatic vessels of 
tumour samples compared to normal tissue, which along with the increased stage of 
lymphadenopathy in cases with reduced CD9 expression suggests a role for this 
tetraspanin in preventing lymphatic spread. A third study of 78 oral cancers again 
confirmed the increased metastatic potential of tumours with lower CD9 expression, 
with higher incidence of cervical lymphadenopathy and poorer outcome31. Loss of 
CD9 expression at the invasive front of the tumours was noted in these cases 
suggesting a role for CD9 in cell adhesion and invasion.  
CD9 has also been shown to exert an effect on EGFR, with complexes of CD9, 
EGFR and β1 integrin co-localised in areas of cell-cell interaction. Through EGF 
induced EGFR receptor internalisation, CD9 has also been shown to attenuate 
EGFR signalling by reducing cell surface EGFR expression26. Additional indirect 
effects on the EGF receptor occur through its receptor ligands. CD9 not only binds to 
Transforming growth factor α (TGF-α), but also affects its maturation, cell-surface 
presentation and cell-surface distribution. CD9 stabilises membrane bound TGF-α 
preventing its cleavage to produce free ligand that may circulate and stimulate EGF 
receptors at distant sites, instead stimulating juxtacrine EGFR activation. This 
alteration in EGF receptor stimulation leads ultimately to differences in the effect of 
receptor activation. In the same series of experiments, co-expression of CD9 and 
TGFα were found to increase cellular adhesion and decrease migratory potential, 
compared to cells in which only one or other were expressed32,33. These results taken 
together might suggest that the consequences of decreased CD9 expression in OED 
are not driven through a direct effect, but through the alteration in balance of EGFR 
activation. This would be in keeping with the finding from the experiments conducted 
here, demonstrating increased EGFR expression as a prognostic variable on 
univariate analysis, despite no obvious direct correlation seen between the 
expression patterns of the two markers. 
Results from studies assessing CD151 are more contradictory. Increased expression 
of CD151 conferred a significantly poorer prognosis in 73 gingival squamous cell 
carcinomas34. However, a recent publication found no prognostic significance of 
CD151 expression in 83 oral cancer cases, despite the widespread expression of the 
protein35. This difference may be due to inconsistent methodologies between the two 
studies. Interestingly, the authors of the latter study did detect a significant 
association between CD151 and EGFR, both of which were also found at the 
invasive front along with the α3β1 integrin (which is also known to form complexes 
with CD151). The suggestion from this study was that CD151 acts to modulate and 
coordinate an interaction between EGFR and α3β1 integrin. This would be consistent 
with the findings here of upregulation of both CD151 and EGFR conferring a worse 
prognosis in cases of OED.  
Increased COX-2 expression is known to occur in premalignant tissues in many sites, 
including the colon, bladder and stomach36-38. Similar upregulation occurs in 
premalignant lesions and cancers of the head and neck. Cross sectional studies 
have all demonstrated an increased expression of COX-2 in premalignant tissue 
compared to normal mucosa39. This finding has been replicated in other studies, 
along with a significant increase in COX-2 expression with increasing severity of 
dysplasia40,41. Despite the interest in COX enzymes as biomarkers in carcinogenesis, 
until now, no longitudinal studies have examined their role as predictors of malignant 
transformation of OED in the head and neck. We have demonstrated not only that 
COX2 has a significant prognostic potential, but also that the risk of malignant 
transformation appears to escalate with increasing COX2 expression.  
EGFR over expression is known to occur in oral premalignant lesions18. In contrast to 
the results presented here, Benchekroun et al examining an cohort of oral 
premalignant lesions failed to show a statistically significant risk of progression to 
oral squamous cell cancer in patients with elevated EGFR immunoreactivity, despite 
high EGFR expression occurring in 71% of the patients42. This disparity may be 
explained by over two thirds of that particular cohort having a histological diagnosis 
of hyperplasia only without dysplasia. The prognostic potential of EGFR on univariate 
analysis in this cohort would support the hypothesis of treating these high-risk lesions 
with EGFR antagonists. Furthermore, evidence is beginning to emerge about the 
interaction between EGFR and COX2, CD9 and CD151. This also raises the 
possibility of multimodal approaches to chemoprevention in the management of oral 
premalignant lesions.  
Limitations of the study 
Although 4 of the biomarkers were prognostic in this study, the thresholds identified 
to differentiate between cases likely or not to progress (CD9, CD151 and EGFR) are 
data driven, and therefore possibly unique to this dataset. In this respect, the results 
must be viewed with caution and are perhaps best considered as representing a 
hypothesis-generating group. A validation cohort would be required to test these 
thresholds. Furthermore, it was not possible to construct a prognostic classifier 
based on the numbers in this study and so any validation cohort would need to be 
larger to enable this.  
Despite being one of the largest cohorts of oral dysplasia used to date in assessing 
the prognostic ability of biomarkers, there remain the same limitations such as 
inadequate data collection and variability in the treatment of similar lesions from 
individuals at different institutions that affect all retrospectively collected cohorts. As 
an example of this, while some studies have reported higher transformation rates of 
oral leukoplakia in females and from particular anatomical areas (lateral border of 
tongue and floor of mouth) other recent large cohort studies have similarly to here, 
failed to demonstrate this8,43,44. It is possible that this difference may be explained in 
part because of difference in cohorts (e.g. in this study all cases were OED, whereas 
in others leukoplakia without dysplasia were also included). Poor clinical recording 
did not allow a sub site analysis of lesions of the tongue to be performed. This meant 
all cases affecting the tongue (the largest site numerically) were analysed together, 
potentially obscuring a significant effect of anatomical site. These limitations may 
only be improved by the prospective enrollment of patients with OED into clinical 
trials.  
Conclusions 
This study, using one of the largest multicenter cohorts of OED in the literature, 
demonstrates 4 biomarkers (EGFR, CD151, CD9 and COX2) with a prognostic ability. 
It is also the first study to examine both the expression and prognostic ability of the 
tetraspanins in OED. If validated, these results may help improve identification of 
those patients at highest risk of malignant transformation and also suggests other 
avenues for chemoprevention and chemotherapeutics in the treatment of this 
condition.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 1:  Clinical characteristics of cohort (number and percent) with prognostic 
  ability by univariate logistic regression (p value) 
 
 
Histological grade 0.0002 
Mild 69 (47)  
Moderate 50 (24)  
Severe 27 (18)  
CIS   2 (1)  
Gender 
 
0.14 
Male 76 (51)  
Female 72 (49)  
Site of lesion 
 
0.73 
Tongue 69 (47)  
Floor of mouth 20 (13)  
Palate 18 (12)  
Buccal 38 (26)  
Retromolar   3 (2)  
Morphology of lesion 
 
0.03 
White patch 94 (63)  
Red patch 15 (10)  
Speckled patch 13 (9)  
Ulcer 22 (15)  
Lump   4 (3)  
Alcohol consumption 0.61 
>21 U/week 23 (15)  
<21 U/week 58 (40)  
None 44 (30)  
Unknown 23 (15)  
Smoking status  0.29 
Current  69 (47)  
Ex   9 (6)  
Non 47 (32)  
Unknown 23 (15)  
 
  
  
Table 2: Prognostic ability of individual biomarkers on univariate analysis using 
logistic and Cox regression (p values) 
 
 
 
 
 
 
 
 
 
 
 
Table 3:  Multivariate analysis demonstrating hazard ratios for the best 
combination of clinical factors and biomarkers in predicting malignant 
progression by backwards-variable selection 
 
 
 
 
 
 
 
 
 
 
Biomarker Univariate 
analysis 
(Logistic) 
Univariate 
analysis 
(Cox) 
COX2 0.003 0.008 
CD9 0.02 0.02 
CD151 0.02 0.33 
EGFR 0.04 0.04 
CD82 0.62 0.69 
Her2 0.73 0.50 
Variable Hazard ratio (95% CI) p value Higher risk group 
Grade 1.64 (1.12, 2.40) 0.01 High grade 
COX2 1.12 (1.02, 1.24) 0.02 High score 
CD9 0.88 (0.80, 0.97) 0.01 Low score 
  
Figure 1: Representative tetraspanin immunohistochemistry. Tiles a-c (CD151), 
d-f (CD82) and g-i (CD9), demonstrate increasing expression from 
scores of 2 (top row) to 6 (middle row) to 12 (bottom row). All 3 
tetraspanin biomarkers exhibit membranous staining. 
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Figure 2:  Representative immunohistochemistry. Tiles a-c (COX2) and d-f 
(EGFR) display increasing expression from scores of 2 (top row), to 6 
(middle row) to 12 (bottom row). COX2 demonstrates predominantly 
cytoplasmic staining, while EGFR is strongly membranous. The 
strongest her2 staining was scored at 3/12 (i). Some cases 
demonstrated both cytoplasmic and membranous staining, (h) and 
were considered positive. Where only cytoplasmic staining occurred 
(g) this was considered negative and given a score of 0.  
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Figure 3: Oral cancer free survival utilising different ordered scoring thresholds 
  for CD9, CD151, EGFR and COX2     
 
 
  
CD9 
p<0.0001 
CD151 
p=0.0002 
p=0.006 
p=0.002 
COX2 EGFR 
Supplementary table 1:  Monoclonal antibodies and optimisations used in this 
study 
 
Marker Antibody 
dilution 
pH  Antibody clone 
EGFR  1:50 6.0 Cell signalling rabbit monoclonal antibody clone: D38B1 Cell 
signaling technologies®, New England Biolabs (UK) Ltd, UK 
COX-2 1:3250 7.8 Novocastra
TM
 mouse monoclonal antibody clone: 4H12, Leica 
Biosystems Newcastle Ltd, Newcastle, UK 
CD9 1:600 7.8 Novocastra
TM
 mouse monoclonal antibody clone: 72F6 Leica 
Biosystems Newcastle Ltd, Newcastle, UK 
CD151 1:900 7.8 Novocastra
TM
 mouse monoclonal antibody clone: RLM30 Leica 
Biosystems Newcastle Ltd, Newcastle, UK 
CD82 1:25 6.0 Novocastra
TM
 mouse monoclonal antibody clone: 5B5 Leica 
Biosystems Newcastle Ltd, Newcastle, UK 
Her2 1:50 6.0 Novocastra
TM
 mouse monoclonal antibody clone: NCL-CB11 
Leica Biosystems Newcastle Ltd, Newcastle, UK 
 
 
 
Supplementary table 2:  Agreement between raters when scoring intensity and 
proportion of each immunohistochemical marker 
 
Kappa 
Intraclass Correlation 
Coefficient 
 
Intensity Proportion Intensity Proportion 
COX2 0.66 0.85 0.85 0.90 
CD9 0.72 0.79 0.87 0.88 
CD151 0.73 0.78 0.86 0.85 
CD82 0.91 0.84 0.96 0.89 
EGFR 0.77 0.74 0.87 0.82 
Her2 1.0 1.0 1.0 1.0 
  
Supplementary table 3: Mean consensus immunohistochemical scores for each 
marker by histological grade and progression status 
 
  Mean immunohistochemical score (standard deviation) 
OED 
grade 
Progressor 
(no. of cases) 
COX2 CD9 CD151 CD82 EGFR Her2 
Mild 
No (62) 5.8 (3.4) 7.0 (3.6) 3.8 (3.1) 2.6 (2.9) 6.3 (3.6) 0.2 (0.9) 
Yes (7) 6.9 (2.5) 3.0 (3.5) 5.0 (3.1) 1.6 (1.3) 6.3 (2.9) 0.0 
Total (69) 5.9 (3.3) 6.6 (3.7) 4.0 (3.1) 2.5 (2.8) 6.3 (3.5) 0.2 (0.9) 
Moderate 
No (32) 5.1 (3.4) 6.9 (4.0) 3.8 (3.4) 2.6 (2.9) 6.8 (3.4) 0.2 (0.6) 
Yes (18) 7.0 (3.1) 5.5 (3.4) 5.8 (2.2) 2.8 (2.8) 7.3 (3.3) 0.3 (1.1) 
Total (50) 5.8 (3.4) 6.4 (3.9) 4.5 (3.2) 2.6 (2.9) 7.0 (3.4) 0.2 (0.8) 
Severe/ 
CIS 
No (15) 5.8 (3.1) 5.9 (3.0) 4.8 (4.3) 1.9 (2.0) 7.1 (3.8) 0.0 
Yes (13) 8.8 (3.1) 5.7 (5.0) 4.9 (3.0) 1.9 2.3) 9.8 (3.1) 0.1 (0.5) 
Total (28) 7.2 (3.4) 5.8 (4.0) 4.9 (3.7) 1.9 (2.1) 8.4 (3.7) 0.1 (0.4) 
Total 
No (109) 5.6 (3.3) 6.8 (3.6) 4.0 (3.3) 2.5 (2.8) 6.6 (3.5) 0.2 (0.8) 
Yes (39) 7.6 (3.1) 5.1 (4.1) 5.3 (2.6) 2.3 (2.4) 8.0 (3.4) 0.2 (0.8) 
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